CTOR · Citius Oncology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-09-19 | HOLUBIAK MYRON Z |
Director, Secretary |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
850,000 |
| 2025-09-19 | Mayersohn Joel David |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
300,000 |
| 2025-09-19 | Holuka Eugene Myron |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
300,000 |
| 2025-09-19 | Mazur Leonard L |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
1,700,000 |
| 2025-09-19 | Czuczman Myron |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
825,000 |
| 2025-09-19 | Bartushak Jaime |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
825,000 |
| 2025-09-19 | Dutia Suren G |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
300,000 |
| 2025-09-19 | MCGRATH DENNIS M |
President and CFO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
300,000 |
| 2025-09-19 | Webb Carol |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
300,000 |
| 2025-09-19 | Smith Robert Joseph |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Common Stock
|
300,000 |
| 2025-07-28 | Mayersohn Joel David |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
The shares were acquired through a distribution in kind to limited partners of 10XYZ Holdings, which was the Sponsor of TenX Keane Acquisition ("TenX"), the legacy entity of Citius Oncology, Inc. |
Common Stock
|
21,228 |
| 2024-12-12 | Czuczman Myron |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options were granted December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, provided that Optionee provides Continuous Service to the Company as of each such vesting date. |
Stock Option (Right to Buy)
|
400,000 |
| 2024-12-12 | HOLUBIAK MYRON Z |
Director, Secretary |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options were granted December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, provided that Optionee provides Continuous Service to the Company as of each such vesting date. |
Stock Option (Right to Buy)
|
300,000 |
| 2024-12-12 | Mayersohn Joel David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date |
Stock Option (Right to Buy)
|
250,000 |
| 2024-12-12 | MCGRATH DENNIS M |
President and CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date |
Stock Option (Right to Buy)
|
125,000 |
| 2024-12-12 | Smith Robert Joseph |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
Stock Option (Right to Buy)
|
125,000 |
| 2024-12-12 | Bartushak Jaime |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options were granted December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, provided that Optionee provides Continuous Service to the Company as of each such vesting date. |
Stock Option (Right to Buy)
|
400,000 |
| 2024-12-12 | HOLUBIAK MYRON Z |
Director, Secretary |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. |
Stock Option (Right to Buy)
(I)
|
50,000 |
| 2024-12-12 | Mazur Leonard L |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options were granted December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, provided that Optionee provides Continuous Service to the Company as of each such vesting date. |
Stock Option (Right to Buy)
|
800,000 |
| 2024-12-12 | Dutia Suren G |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
Stock Option (Right to Buy)
|
125,000 |
| 2024-12-12 | Webb Carol |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
Stock Option (Right to Buy)
|
125,000 |
| 2024-12-12 | Holuka Eugene Myron |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
Stock Option (Right to Buy)
|
125,000 |
| 2024-08-12 | HOLUBIAK MYRON Z |
Director, Secretary |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. |
Stock Option (Right to Buy)
|
1,500,000 |
| 2024-08-12 | Bartushak Jaime |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | Czuczman Myron |
Chief Medical Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | HOLUBIAK MYRON Z |
Director, Secretary |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
500,000 |
| 2024-08-12 | MCGRATH DENNIS M |
President and CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., is 100% vested. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
150,000 |
| 2024-08-12 | Dutia Suren G |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | Mazur Leonard L |
Director, Chief Executive Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | Mazur Leonard L |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
1,233,333 |
| 2024-08-12 | Czuczman Myron |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
466,667 |
| 2024-08-12 | Czuczman Myron |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. |
Stock Option (Right to Buy)
|
1,400,000 |
| 2024-08-12 | HOLUBIAK MYRON Z |
Director, Secretary |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | Webb Carol |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., is 100% vested. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
150,000 |
| 2024-08-12 | Dutia Suren G |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., is 100% vested. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
150,000 |
| 2024-08-12 | Smith Robert Joseph |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | Bartushak Jaime |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
466,667 |
| 2024-08-12 | Bartushak Jaime |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. |
Stock Option (Right to Buy)
|
1,400,000 |
| 2024-08-12 | Holuka Eugene Myron |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | Holuka Eugene Myron |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., is 100% vested. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. |
Stock Option (Right to Buy)
|
150,000 |
| 2024-08-12 | Mazur Leonard L |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. |
Stock Option (Right to Buy)
|
3,700,000 |
| 2024-08-12 | MCGRATH DENNIS M |
President and CFO |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-12 | Webb Carol |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2022-10-13 | Jiang Cathy |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2022-10-13 | Hartzband Brian Shawn |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2022-10-13 | Mayersohn Joel David |
Director |
Other↑
|
No Securities Owned
|
0 |